|
8 结论
虽然前列腺素类药物是一类安全性与耐受性良好的药物，仅5%患者由于不良反应而停止使用该类药物。全身不良反应一般仅限于头痛和上呼吸道症状。但这类药物的局部不良反应常见，拉坦前列腺素、曲伏前列腺素、贝美前列腺素可分别造成3～15%、35～50%、15～45%患者结膜充血。许多患者中结膜充血还比较轻，仅3%患者因为结膜充血而停止使用曲伏前列腺素和贝美前列腺素。长期使用前列腺素类药物的另外一个常见不良反应是虹膜色素沉着，多见于多颜色虹膜。虹膜颜色改变发生率从1.1～2.3%不等。因此，临床使用前列腺素类药物需要密切注意不良反应。另外，由于前列腺素类药物价格昂贵，长期应用大多数患者经济能力难以承受，因此迫切需要加大前列腺素类药物国产化研究与生产。
【参考文献】
1 Quaranta L, Pizzolante T, Riva I, et al. 24hour intraocular pressure and blood pressure levels with bimatoprost versus latanoprost in patients with normaltension glaucoma[J]. Br J Ophthalmol, 2008, 92(5): 12271231.
2 Yildirim N, Sahin A, Gultekin S. The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with openangle glaucoma[J]. J Glaucoma, 2008, 17(1):3639.
3 Ikeda Y, Mori K, Ishibashi T, et al.Effects of switching from topical betablockers to latanoprost on intraocular pressure in patients with normaltension glaucoma[J]. J Ocul Pharmacol Ther, 2008, 24(2):230234.
4 Enoki M, Saito J, Hara M, et al. Additional reduction in intraocular pressure achieved with latanoprost in normaltension glaucoma patients previously treated with unoprostone[J]. Jpn J Ophthalmol, 2006, 50(4):334337.
5 Quaranta L, Miglior S, Floriani I, et al. Effects of the timololdorzolamide fixed combination and latanoprost on circadian diastolic ocular perfusion pressure in glaucoma[J]. Invest Ophthalmol Vis Sci, 2008, doi: 10.1167/iovs.081744.
6 Rismanchian A, Eslami F, Moeini H, et al. Efficacy of the latanoprost versus timolol/dorzolamide combination therapy in patients with primary open angle glaucoma[J]. Saudi Med J, 2008, 29(3):384387.
7 Martinez A，Sanchez M. Bimatoprost/timolol fixed combination vs latanoprost/timolol fixed combination in openangle glaucoma patients[J]. Eye,2008.148.
8 Goldberg I, Li X, Selaru P, et al. A 5year, randomized, openlabel safety study of latanoprost and usual care in patients with openangle glaucoma or ocular hypertension[J]. Eur J Ophthalmol，2008, 18(3):408416.
9 Ang G S, Kersey J P, Shepstone L, et al. The effect of travoprost on daytime intraocular pressure in normaltension glaucoma: a randomised controlled trial[J]. Br J Ophthalmol, 2008, 92(8):11291133.
10 Chiselita D. Evaluation of the role of travoprost 0.004% ophthalmic solution in the management of open angle glaucoma and ocular hypertensive patients[J]. Oftalmologia, 2007, 51(2):8186.
11 Alagoz G, Gurel K, Bayer A, et al. A comparative study of bimatoprost and travoprost: effect on intraocular pressure and ocular circulation in newly diagnosed glaucoma patients[J]. Ophthalmologica, 2008, 222(2):8895.
12 Lafuma A，Berdeaux G. Costs and effectiveness of travoprost versus a dorzolamide + timolol fixed combination in firstline treatment of glaucoma: analysis conducted on the United Kingdom General Practitioner Research Database[J]. Curr Med Res Opin, 2007, 23(12):30093016.
13 Topouzis F, Melamed S, DaneshMeyer H, et al. A 1year study to compare the efficacy and safety of oncedaily travoprost 0.004%/timolol 0.5% to oncedaily latanoprost 0.005%/timolol 0.5% in patients with openangle glaucoma or ocular hypertension[J]. Eur J Ophthalmol, 2007, 17(2):183190.
14 Konstas A G, Hollo G, Irkec M, et al. Diurnal IOP control with bimatoprost versus latanoprost in exfoliative glaucoma: a crossover, observermasked, threecentre study[J]. Br J Ophthalmol, 2007, 91(6):757760.
15 Martin E, MartinezdelaCasa J M, GarciaFeijoo J, et al. A 6month assessment of bimatoprost 0.03% vs timolol maleate 0.5%: hypotensive efficacy, macular thickness and flare in ocularhypertensive and glaucoma patients[J]. Eye, 2007, 21(2):164168.
16 Trattler W, Noecker R J， Earl M L. A multicentre evaluation of the effect of patient education on acceptance of hyperaemia associated with bimatoprost therapy for glaucoma or ocular hypertension[J]. Adv Ther, 2008, 25(3):179189.
17 Jampel H D, Bacharach J, Sheu W, et al. Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure[J]. Am J Ophthalmol, 2002, 134(6):863871.
18 Saito Y, Saeki T, Sugiyama K.[Longterm effects of isopropyl unoprostone monotherapy on intraocular pressure and visual field for normaltension glaucoma and primary openangle glaucoma patients][J]. Nippon Ganka Gakkai Zasshi, 2006, 110(9):717722.
19 Kimura I, Shinoda K, Tanino T, et al. Effect of topical unoprostone isopropyl on optic nerve head circulation in controls and in normaltension glaucoma patients[J]. Jpn J Ophthalmol, 2005, 49(4):287293.
20 Sharpe E D, Henry C J, Mundorf T K, et al. Brimonidine 0.2% vs unoprostone 0.15% both added to timolol maleate 0.5% given twice daily to patients with primary openangle glaucoma or ocular hypertension[J]. Eye, 2005, 19(1):3540.
21 Day D G, Schacknow P N, Wand M, et al. Timolol 0.5%/dorzolamide 2% fixed combination vs timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients with primary openangle glaucoma or ocular hypertension[J]. Am J Ophthalmol, 2003, 135(2):138143.
22 Sutton A, Gilvarry A, Ropo A. A comparative, placebocontrolled study of prostanoid fluoroprostaglandinreceptor agonists tafluprost and latanoprost in healthy males[J]. J Ocul Pharmacol Ther, 2007, 23(4):359365.
23 Nilsson S F, Drecoll E, LutjenDrecoll E, et al.The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey[J]. Invest Ophthalmol Vis Sci, 2006, 47(9):40424049.
24 Toris C B, Zhan G L, Feilmeier M R, et al. Effects of a prostaglandin DP receptor agonist, AL6598, on aqueous humor dynamics in a nonhuman primate model of glaucoma[J]. J Ocul Pharmacol Ther, 2006, 22(2):8692. 上一页 [1] [2] |
